Compare · LIVN vs MOVE
LIVN vs MOVE
Side-by-side comparison of LivaNova PLC (LIVN) and Corvex Inc. (MOVE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIVN and MOVE operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.37B, about 17.0x MOVE ($256.8M).
- Over the past year, LIVN is up 40.3% and MOVE is up 72.0% - MOVE leads by 31.7 points.
- LIVN has been more active in the news (7 items in the past 4 weeks vs 5 for MOVE).
- LIVN has more recent analyst coverage (20 ratings vs 0 for MOVE).
- Company
- LivaNova PLC
- Corvex Inc.
- Price
- $79.41+1.50%
- $8.74-2.78%
- Market cap
- $4.37B
- $256.8M
- 1M return
- -1.38%
- -32.14%
- 1Y return
- +40.34%
- +72.01%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 5
- Recent ratings
- 20
- 0
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Corvex Inc.
Movano Inc., a technology company, develops a smart wearable and continuous glucose monitoring device. Its device enables individuals and their healthcare partners to measure and manage their health conditions. Movano Inc. was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. The company was incorporated in 2018 and is based in Pleasanton, California.
Latest LIVN
- Chief Innovation Officer Tezel Ahmet exercised 12,692 units of Ordinary Shares at a strike of $52.68, returned $668,740 worth of Ordinary Shares to the company (8,589 units at $77.86), covered exercise/tax liability with 1,428 units of Ordinary Shares and sold $207,942 worth of Ordinary Shares (2,675 units at $77.74) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by LivaNova PLC
- SEC Form IRANNOTICE filed by LivaNova PLC
- SEC Form 10-Q filed by LivaNova PLC
- SEC Form 3 filed by new insider Folli Stefano
- LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- LivaNova to Announce Second-Quarter 2026 Results
- Director Wilver Peter M covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 53% to 10,294 units (SEC Form 4)
- Chief Innovation Officer Tezel Ahmet converted options into 2,965 units of Ordinary Shares and covered exercise/tax liability with 1,032 units of Ordinary Shares, increasing direct ownership by 46% to 6,090 units (SEC Form 4)
Latest MOVE
- Corvex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Corvex Inc.
- Corvex Reports Second Quarter 2026 Results and Provides Business Update
- Corvex to Host Second Quarter 2026 Earnings Call on Friday, August 14, 2026
- Corvex Signs Multi-Year Agreement to Provide NVIDIA Blackwell GPUs
- SEC Form EFFECT filed by Corvex Inc.
- SEC Form 424B7 filed by Corvex Inc.
- Corvex Appoints AI Infrastructure Veteran Michael Craig as Vice President of Architecture and Site Operations
- SEC Form S-1 filed by Corvex Inc.
- Co-Chief Executive Officer Demsey Seth converted options into 5,515,658 shares, increasing direct ownership by 178% to 8,563,155 units (SEC Form 4)